<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20211007052693N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-11-20</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of oral premedication of midazolam, ketamine and dexmedetomidine in sedation and facilitation of separation of children from parents for induction of anesthesia</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of oral premedication of midazolam, ketamine and dexmedetomidine in sedation and facilitation of separation of children from parents for induction of anesthesia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-12-11</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>153</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/59366</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this double-blind randomized clinical trial study, 153 patients 2 to 10 years old, candidates for elective surgery, enter the study after obtaining the informed consent of the patient's parents or guardian.
None of the children should receive sedatives before entering the operating room and they are randomly divided into 3 groups by block method, Blinding description: Unaware of the type of drug being prescribed, the intern pours the drug under the child's tongue by the syringe containing the intervention drug to be swallowed with a short pause in the mouth.
The exact method is that in each group, after calculating the amount of drug based on the child's weight, to standardize and create an acceptable taste, one milliliter of 20% dextrose solution is added to the calculated intervention drug for each patient. Finally, to match the groups, the volume of the prescribed material with distilled water is increased to 5 ml.
This double-blind study will be performed in such a way that patients with informed consent to enter the plan will not be aware of the type of drug used.
Also, the intern, who is responsible for completing the questionnaires and recording the data, is not aware of the patients in the study groups and will not be aware of the type of oral solution. And will only complete the questionnaires based on the numbers to be assigned to the operating room by the anesthesiologist in charge of the project.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: anesthesia. Condition 2: sedation.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The first group: midazolam half mg / kg (midazolam ampoule made by Caspian Tamin Company Rasht - Iran) after calculating the amount of drug based on the weight of the child, to equalize and create an acceptable taste of one ml of 20% dextrose solution to the intervention drug is calculated Is added for each patient, and finally, to match the groups, the volume of the prescribed substance with distilled water is increased to 5 ml, and by the intern, who is unaware of the type of drug prescribed, it is poured into the syringes containing the intervention drug under the child's tongue. To be swallowed with a little pause in the mouth. Intervention 2: Intervention group: The second group: Ketamine 5 mg/kg (ketamine consumed by Rotex Medica - Germany) after calculating the amount of drug based on the weight of the child, to equalize and create an acceptable taste of one ml of 20% dextrose solution to the intervention drug is calculated Is added for each patient, and finally, to match the groups, the volume of the prescribed substance with distilled water is increased to 5 ml, and by the intern, who is unaware of the type of drug prescribed, it is poured into the syringes containing the intervention drug under the child's tongue. To be swallowed with a little pause in the mouth. Intervention 3: Intervention group: The third group: Dexmedetomidine 4 micrograms per kilogram orally (dexmedetomidine made by Elixir Company - Iran) after calculating the amount of drug based on the weight of the child, to equalize and create an acceptable taste of one ml of 20% dextrose solution to the intervention drug is calculated Is added for each patient, and finally, to match the groups, the volume of the prescribed substance with distilled water is increased to 5 ml, and by the intern, who is unaware of the type of drug prescribed, it is poured into the syringes containing the intervention drug under the child's tongue. To be swallowed with a little pause in the mouth.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
After the publication of the article, confidential information such as patient and hospital details, etc. will be deleted and other information will be provided to researchers.

When:
After publishing the article

To whom:
Medical specialists

Conditions:
Medical professionals can access the data for research purposes.

Where to obtain:
Email the corresponding author

How to obtain:
Official and academic email to the corresponding author

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hesameddin Modir</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vali-ye-Asr Hospital of Arak, Hazrat Valiasr Square</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3814957558</zip>
        <telephone>+98 86 3222 2003</telephone>
        <email>he_modir@arakmu.ac.ir</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hesameddin Modir</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vali-ye-Asr Hospital of Arak, Hazrat Valiasr Square</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3814957558</zip>
        <telephone>+98 86 3222 2003</telephone>
        <email>he_modir@arakmu.ac.ir</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 2 to 7 years
Weight between 10 and 30 kg
ASA I or II
Candidate for elective surgery except for fractures
Absence of any fracture operation
No history of allergies
Absence of liver, kidney and cardiopulmonary disorders
Lack of long-term use of anticonvulsant drugs, sleep disorders
Absence of speech or communication problems
Absence of gastrointestinal disorders (due to oral administration of drugs)
The duration of surgery is less than 120 minutes
Consent of parents and guardians of the child</inclusion_criteria>
      <agemin>2 years</agemin>
      <agemax>10 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Any unpredictable complications around the operation that affect the variables being evaluated</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The first group: midazolam half mg / kg (midazolam ampoule made by Caspian Tamin Company Rasht - Iran) after calculating the amount of drug based on the weight of the child, to equalize and create an acceptable taste of one ml of 20% dextrose solution to the intervention drug is calculated Is added for each patient, and finally, to match the groups, the volume of the prescribed substance with distilled water is increased to 5 ml, and by the intern, who is unaware of the type of drug prescribed, it is poured into the syringes containing the intervention drug under the child's tongue. To be swallowed with a little pause in the mouth.</i_keyword>
      <i_keyword>Intervention group: The second group: Ketamine 5 mg/kg (ketamine consumed by Rotex Medica - Germany) after calculating the amount of drug based on the weight of the child, to equalize and create an acceptable taste of one ml of 20% dextrose solution to the intervention drug is calculated Is added for each patient, and finally, to match the groups, the volume of the prescribed substance with distilled water is increased to 5 ml, and by the intern, who is unaware of the type of drug prescribed, it is poured into the syringes containing the intervention drug under the child's tongue. To be swallowed with a little pause in the mouth.</i_keyword>
      <i_keyword>Intervention group: The third group: Dexmedetomidine 4 micrograms per kilogram orally (dexmedetomidine made by Elixir Company - Iran) after calculating the amount of drug based on the weight of the child, to equalize and create an acceptable taste of one ml of 20% dextrose solution to the intervention drug is calculated Is added for each patient, and finally, to match the groups, the volume of the prescribed substance with distilled water is increased to 5 ml, and by the intern, who is unaware of the type of drug prescribed, it is poured into the syringes containing the intervention drug under the child's tongue. To be swallowed with a little pause in the mouth.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sedation score. Timepoint: The observation sedation score is measured before the medication is prescribed (midazolam, ketamine, and dexmedetomidine) and then when the child is separated from the parents. Method of measurement: Determine the sedation score by observing based on scoring from 1 to 5 based on the table from 1 to 5, respectively: agitated, alert, calm, drowsy and asleep.</prim_outcome>
      <prim_outcome>Ease of separation score. Timepoint: When separating children from their parents. Method of measurement: Determining the ease of separation score by observation based on scoring from 1 to 4 according to the table from 1 to 4, respectively: unafraid and cooperative - slight fear or crying quiet with assurance - moderate fear, crying not quiet with assurance - crying, need for restraint.</prim_outcome>
      <prim_outcome>Acceptance of drug. Timepoint: When inducing anesthesia inside the operating room. Method of measurement: Children are transported into the operating room and then inhaled anesthesia with a mask is induced in all groups using soufflore gas (4-8%). The acceptance rate of induction of anesthesia is determined based on the scoring of the table. Respectively from 1 to 3: refused to accept - accept with difficulty - accept without complaining.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Mean blood pressure. Timepoint: Under monitoring from 30 minutes before anesthesia, every 5 minutes from the time of sedation until induction of anesthesia, every 15 minutes throughout the operation and in recovery until full awakening, re-measured in case of side effects up to 24 hours after surgery. Method of measurement: arm sphygmomanometer In millimetres of mercury.</sec_outcome>
      <sec_outcome>Heart rate. Timepoint: Under monitoring from 30 minutes before anesthesia, every 5 minutes from the time of sedation until induction of anesthesia, every 15 minutes throughout the operation and in recovery until full awakening, re-measured in case of side effects up to 24 hours after surgery. Method of measurement: Cardiac monitoring and finger pulse oximetery.</sec_outcome>
      <sec_outcome>Arterial oxygen saturation. Timepoint: Under monitoring from 30 minutes before anesthesia, every 5 minutes from the time of sedation until induction of anesthesia, every 15 minutes throughout the operation and in recovery until full awakening, re-measured in case of side effects up to 24 hours after surgery. Method of measurement: Finger pulse oximetery.</sec_outcome>
      <sec_outcome>Side effects (nausea and vomiting, hypotension, bradycardia). Timepoint: In the postoperative period, patients will be monitored and followed for 24 hours for possible side effects. Method of measurement: Nausea and vomiting with observation and examination - Hypotension (low blood pressure more than 20% of primary blood pressure) with arm sphygmomanometer - Bradycardia (heart rate less than 70 beats per minute) with heart monitoring and finger pulse oximetry.</sec_outcome>
      <sec_outcome>Time to get Aldrete Score 8 and above. Timepoint: One turn (after the end of the operation until reaching the Aldrete score 8 and above). Method of measurement: In minutes from the end of the operation until reaching the Aldrete score of 8 and above In the recovery room according to the table The Modified Aldrete Postanesthesia Score in pediatric.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-09-05</approval_date>
        <contact_name>Ethics committee of Arak University of Medical Sciences</contact_name>
        <contact_address>Sardasht, Basij Square, University of Medical Sciences, University Complex of the Holy Prophet (PBUH), Deputy of Research and Technology Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
